Intracellular trafficking of bio-nanocapsule-liposome complex: Identification of fusogenic activity in the pre-S1 region of hepatitis B virus surface antigen L protein.

Bio-nanocapsules (BNCs) are a hollow nanoparticle consisting of about 100-nm liposome (LP) embedding about 110 molecules of hepatitis B virus (HBV) surface antigen (HBsAg) L protein as a transmembrane protein. Owing to the human hepatocyte-recognizing domains on the N-terminal region (pre-S1 region), BNCs have recently been shown to attach and enter into human hepatic cells using the early infection mechanism of HBV. Since BNCs could form a complex with an LP containing various drugs and genes, BNC-LP complexes have been used as a human hepatic cell-specific drug and gene-delivery system in vitro and in vivo. However, the role of BNCs in cell entry and intracellular trafficking of payloads in BNC-LP complexes has not been fully elucidated. In this study, we demonstrate that low pH-dependent fusogenic activity resides in the N-terminal part of pre-S1 region (NPLGFFPDHQLDPAFG), of which the first FF residues are essential for the activity, and which facilitates membrane fusion between LPs in vitro. Moreover, BNC-LP complexes can bind human hepatic cells specifically, enter into the cells via clathrin-mediated endocytosis, and release their payloads mostly into the cytoplasm. Taken together, the BNC portion of BNC-LP complexes can induce membrane fusion between LPs and endosomal membranes under low pH conditions, and thereby facilitate the endosomal escape of payloads. Furthermore, the fusogenic domain of the pre-S1 region of HBsAg L protein may play a pivotal role in the intracellular trafficking of not only BNC-LP complexes but also of HBV.

[1]  R. G. Anderson,et al.  Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation , 1993, The Journal of cell biology.

[2]  A. Brunger,et al.  Neuronal SNAREs do not trigger fusion between synthetic membranes but do promote PEG-mediated membrane fusion. , 2006, Biophysical journal.

[3]  G. Sauerbrey,et al.  Use of quartz vibration for weighing thin films on a microbalance , 1959 .

[4]  Y. Kaneda,et al.  Virosomes: evolution of the liposome as a targeted drug delivery system. , 2000, Advanced drug delivery reviews.

[5]  Joohee Jung,et al.  Chapter 8 - Bio-nanocapsule-liposome conjugates for in vivo pinpoint drug and gene delivery. , 2009, Methods in enzymology.

[6]  Joohee Jung,et al.  Bio-nanocapsule conjugated with liposomes for in vivo pinpoint delivery of various materials. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[7]  A. Kondo,et al.  Gene therapy of liver tumors with human liver-specific nanoparticles , 2007, Cancer Gene Therapy.

[8]  C. Futter,et al.  Multivesicular endosomes containing internalized EGF-EGF receptor complexes mature and then fuse directly with lysosomes , 1996, The Journal of cell biology.

[9]  A. Kondo,et al.  Nanoparticles for the delivery of genes and drugs to human hepatocytes , 2003, Nature Biotechnology.

[10]  E. Hildt,et al.  HBV Life Cycle: Entry and Morphogenesis , 2009, Viruses.

[11]  G. Sauerbrey Verwendung von Schwingquarzen zur Wägung dünner Schichten und zur Mikrowägung , 1959 .

[12]  A. R. Neurath,et al.  Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus , 1986, Cell.

[13]  N. Paran,et al.  The earliest steps in hepatitis B virus infection. , 2003, Biochimica et biophysica acta.

[14]  I. Rodrı́guez-Crespo,et al.  Prediction of a putative fusion peptide in the S protein of hepatitis B virus. , 1994, The Journal of general virology.

[15]  S. Kuroda,et al.  Hepatitis B virus envelope L protein particles. Synthesis and assembly in Saccharomyces cerevisiae, purification and characterization. , 1992, The Journal of biological chemistry.

[16]  S. Harrison Viral membrane fusion , 2008, Nature Structural &Molecular Biology.

[17]  Á. Valverde,et al.  Impairment of Transforming Growth Factor β Signaling in Caveolin-1-deficient Hepatocytes , 2009, The Journal of Biological Chemistry.

[18]  E. Choi,et al.  Efficient and rapid purification of drug- and gene-carrying bio-nanocapsules, hepatitis B virus surface antigen L particles, from Saccharomyces cerevisiae. , 2011, Protein expression and purification.

[19]  M. Schnölzer,et al.  Characterization of a hepatitis B and hepatitis delta virus receptor binding site , 2006, Hepatology.

[20]  H. Britton,et al.  CXCVIII.—Universal buffer solutions and the dissociation constant of veronal , 1931 .

[21]  E. Wisse,et al.  The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer , 2008, Gene Therapy.

[22]  S M Gruner,et al.  Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient. , 1998, Biochimica et biophysica acta.

[23]  U. Haberkorn,et al.  Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein , 2008, Nature Biotechnology.

[24]  Wenhui Li,et al.  Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus , 2012, eLife.

[25]  P. Frederik,et al.  Osmotic and curvature stress affect PEG-induced fusion of lipid vesicles but not mixing of their lipids. , 2002, Biophysical journal.

[26]  H. Schaller,et al.  A Metastable Form of the Large Envelope Protein of Duck Hepatitis B Virus: Low-pH Release Results in a Transition to a Hydrophobic, Potentially Fusogenic Conformation , 2000, Journal of Virology.

[27]  F. Rey,et al.  Virus membrane-fusion proteins: more than one way to make a hairpin , 2006, Nature Reviews Microbiology.

[28]  J. Schneider-Schaulies,et al.  Cellular receptors for viruses: links to tropism and pathogenesis. , 2000, The Journal of general virology.

[29]  T. Block,et al.  Study of the early steps of the Hepatitis B Virus life cycle , 2004, International journal of medical sciences.

[30]  M. Bretscher,et al.  Distinct endocytotic pathways in epidermal growth factor-stimulated human carcinoma A431 cells [published erratum appears in J Cell Biol 1990 Mar;110(3):859] , 1989, The Journal of cell biology.

[31]  E. Choi,et al.  Hepatitis B virus envelope L protein-derived bio-nanocapsules: mechanisms of cellular attachment and entry into human hepatic cells. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[32]  A. Dasgupta,et al.  Interaction of hemoglobin and copper nanoparticles: implications in hemoglobinopathy. , 2006, Nanomedicine : nanotechnology, biology, and medicine.

[33]  A. Kondo,et al.  Physicochemical and immunological characterization of hepatitis B virus envelope particles exclusively consisting of the entire L (pre-S1 + pre-S2 + S) protein. , 2001, Vaccine.

[34]  F. Hughson Structural characterization of viral fusion proteins , 1995, Current Biology.

[35]  K. Kono,et al.  A liposome-based antigen delivery system using pH-sensitive fusogenic polymers for cancer immunotherapy. , 2013, Biomaterials.

[36]  E. Hildt,et al.  Novel cell permeable motif derived from the PreS2-domain of hepatitis-B virus surface antigens , 2000, Gene Therapy.

[37]  J. Albar,et al.  Phospholipid interactions of the putative fusion peptide of hepatitis B virus surface antigen S protein. , 1995, The Journal of general virology.

[38]  F. Szoka,et al.  H+- and Ca2+-induced fusion and destabilization of liposomes. , 1985, Biochemistry.

[39]  S. Urban,et al.  Hepatitis B virus infection initiates with a large surface protein–dependent binding to heparan sulfate proteoglycans , 2007 .